Chemical Design and Pharmacokinetics Enable Precision Psychedelic Therapeutics.
ACS Med Chem Lett January 12, 2026 DOI: 10.1021/acsmedchemlett.5c00780 (opens in new tab) via PubMed
Summary
AI-generated from the abstractRecent patent applications show a strategic shift in psychedelic development from experiential treatments toward chemically and pharmacokinetically precise neurotherapeutics. Four patent applications collectively cover solid-state control of psilocybin, exposure-shaped intramuscular and infusion-based dosing, and chemically diversified monoaminergic scaffolds with defined transporter and receptor pharmacology. These disclosures outline a platform-level evolution toward reproducible, mechanism-informed psychedelic medicines.
Study at a glance
| Characteristics | Review Peer reviewed |
|---|---|
| Key finding | Recent patent applications indicate a strategic shift toward chemically and pharmacokinetically precise neurotherapeutics in psychedelic development. |
Abstract
Recent psychedelic patent activity highlights a strategic shift from experiential framing toward chemically and pharmacokinetically precise neurotherapeutics. Four recent patent applications collectively span solid-state control of psilocybin, exposure-shaped intramuscular and infusion-based dosing, and chemically diversified monoaminergic scaffolds with defined transporter and receptor pharmacology. Together, these disclosures outline a platform-level evolution toward reproducible, mechanism-informed psychedelic medicines.